Treatment-resistant depressive disorder
Drug research and approvals for treatment-resistant depressive disorder: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 129 studies of treatment-resistant depressive disorder are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 129
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Sensation Seeking and TMS Response in TRDNCT07889739 · Not reported · Technical University of Munich · starts May 2, 2024
- French Minds Cohort: a French Longitudinal and Multimodal Cohort of Patients With Major Mood Disorders, Psychotic…NCT07881016 · Not applicable · Fondation FondaMental · starts Jun 11, 2026
- SAINT® Therapy for Memory Problems in Older Adults With Treatment-Resistant DepressionNCT07876908 · Not applicable · BrainHealth Solutions, Inc. · starts Oct 1, 2026
- EEG-Guided Transcranial Magnetic Stimulation for Adults With DepressionNCT07862205 · Not applicable · Mayo Clinic · starts Nov 2, 2026
- Dehydroepiandrosterone (DHEA) as Augmentation of Standard Antidepressants in Treatment-resistant Depression.NCT07843927 · Phase 3 · Charite University, Berlin, Germany · starts Jun 22, 2026
- Behavioural Activation Therapy and Ketamine for Treatment-Resistant DepressionNCT07801703 · Phase 2 / Phase 3 · The Royal's Institute of Mental Health Research · starts Oct 30, 2026
- One-Day cTBS Over the PrecuneusNCT07758010 · Not applicable · Mclean Hospital · starts Sep 8, 2026
- EEG Microstate Parameters and Neuroinflammatory Biomarkers in Patients With Treatment-Resistant Major Depressive…NCT07748091 · Not reported · Istanbul University - Cerrahpasa · starts Jan 1, 2026
- Treatment Resistance in Psychiatric Disorders: the Search for Biological Markers Predictive of Response to TreatmentNCT07741981 · Not applicable · Centre Hospitalier St Anne · starts Aug 20, 2026
Phase 3 12
- PsilocybinSerotonin 2a (5-HT2a) receptor agonist
- KetamineGlutamate [NMDA] receptor negative allosteric modulator
- BupropionDopamine transporter inhibitor
- FluoxetineSerotonin transporter inhibitor
- Lithium carbonateInositol-1(or 4)-monophosphatase 1 inhibitor
- OlanzapineSerotonin 2a (5-HT2a) receptor antagonist
- DextromethorphanSigma opioid receptor agonist
- EsketamineGlutamate [NMDA] receptor negative allosteric modulator
- QuetiapineSerotonin 2a (5-HT2a) receptor antagonist
- VenlafaxineSerotonin transporter inhibitor
- SimvastatinHMG-CoA reductase inhibitor
- MinocyclineBacterial 70S ribosome inhibitor
Phase 2 9
- PropofolGABA-A receptor; anion channel positive allosteric modulator
- MidazolamGABA-A receptor; anion channel positive allosteric modulator
- Fospropofol
- Nitrous oxide
- NV-5138
- AspirinCyclooxygenase inhibitor
- LiafensineMonoamine transporter inhibitor
- AticaprantKappa opioid receptor antagonist
- CX-157
Phase 1 or earlier 2
How its trials ended
387 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 94 whose ending is known, 51% met their primary endpoint, 4% missed it and 45% stopped early.
- Ongoing14939%
- Completed, result not reported10627%
- Met its primary endpoint4812%
- Status unknown3810%
- Stopped: other or unclear287%
- Stopped: enrollment or feasibility72%
- Missed its primary endpoint41%
- Stopped: funding31%
- Stopped: lack of efficacy21%
- Stopped: safety1<1%
- Stopped: sponsor or business decision1<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA